2014;130(14):1452-4.
[Cannabinoid mouth spray brought help to a severely spastic young man].
[Article in Finnish]
Abstract
Cannabinoid was licensed in 2012 for the treatment of spasticity associated with multiple sclerosis in Finland. Spasticity is one of the main symptoms in cerebral palsies and a risk factor of multiple painful anomalies of the skeletal network. We describe a 28-year-old man with severe cerebral palsy, whose quality of life improved and the need for help decreased by using two daily mouth sprays of cannabinoid.
- PMID:
- 25158585
- [PubMed – in process]
-
Publication Types
Publication Types